Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors
Endocrinology Diabetes & Metabolism2017Vol. 1(1), pp. e00005–e00005
Citations Over TimeTop 22% of 2017 papers
Elisabetta Patorno, Chandrasekar Gopalakrishnan, Dorothee B. Bartels, Kimberly G. Brodovicz, Jun S. Liu, Sebastian Schneeweiß
Abstract
Among patients initiating newer diabetes medications between 05/2011-09/2015, those initiating linagliptin had the highest prevalence of moderate to severe renal impairment, suggesting preferential prescribing in routine care. DPP-4 inhibitors overall were among the most frequently chosen agents among T2DM patients with moderate to severe renal impairment between 01/2006-09/2015. Further investigation of the safety and effectiveness of DPP-4 inhibitors in routine care of T2DM patients with renal impairment is needed to either corroborate or discourage current prescribing patterns.
Related Papers
- → Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus(2012)41 cited
- → Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers(2010)28 cited
- → Linagliptin for the treatment of type 2 diabetes(2011)7 cited
- → Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations(2016)26 cited
- → Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus(2012)1 cited